{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=31", "query": { "intervention": "atezolizumab", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 512, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T12:36:48.792Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03050060", "title": "Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Kidney Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Renal Cell Cancer AJCC v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nelfinavir Mesylate", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2017-06-09", "completion_date": "2020-07-12", "has_results": true, "last_update_posted_date": "2022-06-22", "last_synced_at": "2026-10-31T12:36:48.792Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03050060" }, { "nct_id": "NCT03866239", "title": "A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cibisatamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2019-05-07", "completion_date": "2024-03-13", "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-10-31T12:36:48.792Z", "location_count": 7, "location_summary": "Los Angeles, California • Santa Monica, California • Stanford, California + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03866239" }, { "nct_id": "NCT03755791", "title": "Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 837, "start_date": "2018-06-10", "completion_date": "2026-07-31", "has_results": true, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-31T12:36:48.792Z", "location_count": 33, "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03755791" }, { "nct_id": "NCT03821246", "title": "Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Prostate Cancer", "Localized Prostate Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Oh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 68, "start_date": "2019-10-30", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-31T12:36:48.792Z", "location_count": 2, "location_summary": "San Francisco, California • St Louis, Missouri", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03821246" }, { "nct_id": "NCT03726879", "title": "A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 454, "start_date": "2019-01-11", "completion_date": "2023-08-24", "has_results": true, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-10-31T12:36:48.792Z", "location_count": 3, "location_summary": "Kansas City, Missouri • New York, New York • Nashville, Tennessee", "locations": [ { "city": "Kansas City", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03726879" }, { "nct_id": "NCT05488522", "title": "SBRT With Atezo/Bev for HCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "SBRT + atezolizumab and bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 18, "start_date": "2022-09-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-10-31T12:36:48.792Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05488522" }, { "nct_id": "NCT03845166", "title": "A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Malignant", "Renal Cell Carcinoma", "Hormone Receptor Positive Breast Carcinoma", "Metastatic Castration-resistant Prostate Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "XL092", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2019-03-20", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-10-31T12:36:48.792Z", "location_count": 40, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 33 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03845166" }, { "nct_id": "NCT03016312", "title": "A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 759, "start_date": "2017-01-10", "completion_date": "2022-12-20", "has_results": true, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-10-31T12:36:48.792Z", "location_count": 39, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 33 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03016312" }, { "nct_id": "NCT05756907", "title": "Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Platinum-resistant Ovarian Cancer" ], "interventions": [ { "name": "SON-1010", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sonnet BioTherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-09-15", "completion_date": "2026-01-08", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-10-31T12:36:48.792Z", "location_count": 3, "location_summary": "Los Angeles, California • Santa Monica, California • Tampa, Florida", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05756907" }, { "nct_id": "NCT00729664", "title": "Multiple Ascending Dose (MDX1105-01)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer, Multiple Indications" ], "interventions": [ { "name": "Anti-PDL-1 antibody", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 281, "start_date": "2009-02", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-09-07", "last_synced_at": "2026-10-31T12:36:48.792Z", "location_count": 11, "location_summary": "Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00729664" } ] }